These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8877763)

  • 1. Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.
    Shepp DH; Ashraf A; Tang IT; Match ME; Millan C; Pergolizzi R
    J Med Virol; 1996 Aug; 49(4):303-10. PubMed ID: 8877763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
    Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
    Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
    J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant genotype interpretation of resistance to didanosine.
    Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
    Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Resistance of human immunodeficiency virus (HIV) to zidovudine. Genotypic analysis in strains isolated from Chilean patients].
    Vial PA; Vial C; Abarca K; Noriega M; Jiménez G; Labarca J; Gasep J; Palacios O; Pérez C; Acuña G
    Rev Med Chil; 1998 Jan; 126(1):17-26. PubMed ID: 9629750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
    Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
    Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
    J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
    Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC
    J Clin Invest; 1998 Nov; 102(10):1769-75. PubMed ID: 9819361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.
    Holguín A; Dietrich U; Immelmann A; Soriano V
    Antivir Ther; 1998; 3(3):183-6. PubMed ID: 10682136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
    Naugler WE; Yong FH; Carey VJ; Dragavon JA; Coombs RW; Frenkel LM
    J Infect Dis; 2002 Feb; 185(4):448-55. PubMed ID: 11865396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.